These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32718128)

  • 21. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies.
    Finkelstein MT; Mermelstein AG; Parker Miller E; Seth PC; Stancofski ED; Fera D
    Viruses; 2021 Jan; 13(1):. PubMed ID: 33477902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
    Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
    JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of monoclonal antibodies in COVID-19: Role in immunotherapy, vaccine development and viral detection.
    Tabll AA; Shahein YE; Omran MM; Elnakib MM; Ragheb AA; Amer KE
    Hum Antibodies; 2021; 29(3):179-191. PubMed ID: 33998533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency.
    Lang-Meli J; Fuchs J; Mathé P; Ho HE; Kern L; Jaki L; Rusignuolo G; Mertins S; Somogyi V; Neumann-Haefelin C; Trinkmann F; Müller M; Thimme R; Umhau M; Quinti I; Wagner D; Panning M; Cunningham-Rundles C; Laubner K; Warnatz K
    J Clin Immunol; 2022 Feb; 42(2):253-265. PubMed ID: 34893946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of SARS-CoV-2-independent immunoregulatory activity of COVID-19 convalescent plasma.
    Brox R; Achenbach S; Hackstein H
    Transfusion; 2021 Nov; 61(11):3087-3093. PubMed ID: 34546583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and application of therapeutic antibodies against COVID-19.
    Ning L; Abagna HB; Jiang Q; Liu S; Huang J
    Int J Biol Sci; 2021; 17(6):1486-1496. PubMed ID: 33907512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Passive immunization: Paradoxical and traditional method for new pandemic challenge COVID-19.
    Iftikhar A; Jabeen F; Manzoor M; Younis T; Shaheen M
    Acta Microbiol Immunol Hung; 2020 Jul; 67(2):87-90. PubMed ID: 32619190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.
    Harvala H; Robb ML; Watkins N; Ijaz S; Dicks S; Patel M; Supasa P; Wanwisa D; Liu C; Mongkolsapaya J; Bown A; Bailey D; Vipond R; Grayson N; Temperton N; Gupta S; Ploeg RJ; Bolton J; Fyfe A; Gopal R; Simmonds P; Screaton G; Thompson C; Brooks T; Zambon M; Miflin G; Roberts DJ
    Transfus Med; 2021 Jun; 31(3):167-175. PubMed ID: 33333627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measuring accuracy of the neutralizing activity of COVID-19 convalescent plasma.
    Franchini M; Mengoli C; Caruso B; Petilino R; Ballotari A; Glingani C
    Clin Chem Lab Med; 2022 Jan; 60(1):e4-e6. PubMed ID: 34472761
    [No Abstract]   [Full Text] [Related]  

  • 31. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice.
    Pang NY; Pang AS; Chow VT; Wang DY
    Mil Med Res; 2021 Aug; 8(1):47. PubMed ID: 34465396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Passive immunization and its rebirth in the era of the COVID-19 pandemic.
    Pavia CS; Wormser GP
    Int J Antimicrob Agents; 2021 Mar; 57(3):106275. PubMed ID: 33400975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomes.
    Mendoza RP; Fyke W; Daniel D; Gabutan E; Das B; Bajaj H; Easy M; Vasileva A; Colbourn R; Alawad M; Dehghani A; Lin B; Emechebe D; Patel P; Jabbar A; Nikolov DB; Giovaniello D; Kang S; Tatem L; Bromberg K; Augenbraun M; Premsrirut P; Libien J; Norin AJ
    Hum Immunol; 2021 Apr; 82(4):255-263. PubMed ID: 33640208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of COVID-19 Virus Infection by Convalescent Plasma.
    Cheraghali AM; Abolghasemi H; Eshghi P
    Iran J Allergy Asthma Immunol; 2020 May; 19(S1):3-6. PubMed ID: 32534509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19-Convalescent Donors.
    Jahrsdörfer B; Groß R; Seidel A; Wettstein L; Ludwig C; Schwarz T; Körper S; Rojewski M; Lotfi R; Weinstock C; Seifried E; Corman VM; Drosten C; Münch J; Schrezenmeier H
    J Immunol; 2021 Jun; 206(11):2614-2622. PubMed ID: 33980583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19.
    Raadsen MP; Gharbharan A; Jordans CCE; Mykytyn AZ; Lamers MM; van den Doel PB; Endeman H; van den Akker JPC; GeurtsvanKessel CH; Koopmans MPG; Rokx C; Goeijenbier M; van Gorp ECM; Rijnders BJA; Haagmans BL
    J Clin Immunol; 2022 Feb; 42(2):232-239. PubMed ID: 34767118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Passive immune therapies: another tool against COVID-19.
    Estcourt LJ
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):628-641. PubMed ID: 34889410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
    Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
    Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals.
    Markmann AJ; Giallourou N; Bhowmik DR; Hou YJ; Lerner A; Martinez DR; Premkumar L; Root H; van Duin D; Napravnik S; Graham SD; Guerra Q; Raut R; Petropoulos CJ; Wrin T; Cornaby C; Schmitz J; Kuruc J; Weiss S; Park Y; Baric R; de Silva AM; Margolis DM; Bartelt LA
    mSphere; 2021 Aug; 6(4):e0027521. PubMed ID: 34431693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities.
    Casadevall A; Henderson JP; Joyner MJ; Pirofski LA
    J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33621214
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.